RecruitingNCT06669000

Time Required to Dissolve Urate Deposits

Time Required to Dissolve Urate Deposits in Patients With Gout


Sponsor

Assistance Publique - Hôpitaux de Paris

Enrollment

250 participants

Start Date

Sep 24, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

Gout is characterized by episodes of acute arthritis of the lower limbs due to intermittent activation of innate immunity in the joints where urate crystals have formed. These crystals occur when serum urate (SUA) levels have been above 70 mg/L for many years. They can be dissolved by lowering SUA levels to at least 60 mg/L (treat-to-target - T2T - strategy). Once the crystals are dissolved, patients are no longer symptomatic and are considered to be in remission (treat-to-dissolve - T2D - strategy). The presence of crystals and their dissolution during treatment can be monitored by repeated ultrasound (US) scans of the feet and knees. The time required for complete dissolution varies from patient to patient. ReViGore40 is a cohort designed to i) determine the time to complete dissolution of urate deposits in joints when SUA levels are maintained below 40 mg/L, ii) determine the factors (clinical, biological, genetic) associated with the time required for complete dissolution of urate deposits within joints.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying DECT of feet, a biological treatment called DNA sample, and others for people with gout. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTStandard X-Rays

\- Standard X-Rays: feet (Month 0)

DIAGNOSTIC_TESTUltrasound

\- Ultrasound (score 0-24): assessment for DC (Double Contour) sign (0-3), aggregates (0-3), tophi (0-3) at MTP1s (first metatarsophalangeal joints) and DC sign (0-3) at both knees, according to the OMERACT, every 6 months until complete dissolution of urate deposits.

DIAGNOSTIC_TESTDECT of feet

DECT of feet: in tophaceous patients only (Month 0, Month 24)

BIOLOGICALDNA sample

DNA will be collected at Month 0

BIOLOGICALSerum collection

\- Serum will be collected at Month 0, Month 6, Month 12, Month 18, Month 24 , Month 36 and Month 48. For OMICs and epigenetic studies: Month 0, Month 6, Month 24 and Month 36.


Locations(1)

APHP, Lariboisière Hospital, Rheumatology departement

Paris, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06669000


Related Trials